Since 2006, intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) drugs has gradually been used for the treatment of neovascular age-related macular degeneration (ARMD) [1]. The gene discussed is VEGFA; the disease is age-related macular degeneration.